Pressure for increased transparency in pharma can create antitrust risks, says Novartis counsel

Alex Wilts

22 February 2017

Credit: Andrew from Flickr

The wealth of information available about pharmaceutical prices presents antitrust risks in the current political environment, a Novartis in-house lawyer said yesterday.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Alex Wilts

View full biography

Author | Editor, GCR USA

[email protected]

Unlock unlimited access to all Global Competition Review content